Aligos Therapeutics Inc. has patented programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B.
Aligos Therapeutics Inc. has identified programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B (HBV).
The TCF4/β-catenin axis is a key driver of tumor growth, where β-catenin has remained resistant to therapy and is traditionally considered an undruggable protein. At the ACS Fall 2025 meeting, Parabilis Medicines Inc. divulged results of work on hyperstabilized α-helical peptides named helicons that directly bind to β-catenin and block its interaction with TCF transcription factors such as TCF4, as well as inhibit the Wnt signaling pathway.
Heat shock protein family H member 1 (HSPH1) plays a key role in cellular stress and protein homeostasis, and it has been implicated in proliferation, invasion and metastasis of tumor cells. A recent study aimed to investigate the link between HSPH1 and the prognosis of HCC.
The discovery of the ‘Warburg effect’ more than 80 years ago implied that inhibiting tumor cells’ ability to consume abnormally large amounts of glucose could prevent them from growing. Taking advantage of the fact that hexokinase-2 catalyzes the first step of glucose metabolism, researchers at Yıldız Teknik Üniversitesi and collaborators identified novel derivatives of the hexokinase-2 inhibitor lonidamine and identified at least one that was potentially more potent and less toxic.
Sorafenib is a widely used treatment for hepatocellular carcinoma that has advanced beyond surgical resection, but only 30% of patients respond and many develop resistance within half a year. The resistance has been linked to showing greater ‘stemness’ characteristics of tumor cells, such as activation of signaling pathways mediated by Wnt/b-catenin, Hedgehog and PI3K-Akt.
Pilatus Biosciences Inc. has announced a clinical trial collaboration with F. Hoffmann-La Roche Ltd. in support of Pilatus’ upcoming first-in-human phase I trial evaluating PLT-012 in combination with atezolizumab in patients with hepatocellular carcinoma (HCC).
It is hardly news that tumor cells, compared to healthy ones, show metabolic reprogramming that accelerates the production of energy and biosynthetic precursors to support rapid growth. What is newly discovered, in contrast, is the possibility that hepatocellular carcinoma (HCC) tumors that are resistant to systemic therapies show further metabolic reprogramming beyond cells that are therapy sensitive, leading them to produce and store even greater amounts of energy.
Hepatocellular carcinomas (HCCs) are challenging to diagnose due to the tumor heterogeneity and unnoticeable early symptoms. Researchers from Anhui Medical University have developed a novel gallium 68 (68Ga)-labeled radiotracer, named [68Ga]DOTA-AngII, designed to improve the precision of HCC imaging.
Researchers from McMaster University and Espervita Therapeutics Inc. have identified the enzyme ATP citrate lyase (ACLY) as a key metabolic regulator of tumor-immune interactions in hepatocellular carcinoma (HCC) driven by metabolic dysfunction-associated steatohepatitis (MASH).
